Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPM.L Regulatory News (MPM)

  • There is currently no data for MPM

Directorate Change

1 Feb 2010 12:50

RNS Number : 4556G
Minster Pharmaceuticals PLC
01 February 2010
 



 

 

For immediate release

1 February 2010

 

 

 

Minster Pharmaceuticals plc

("Minster" or the "Company")

 

 

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, announces that further to the announcement made on 4 January 2010 regarding Peter Blower's intention to resign as a director of Minster on 31 January 2010, the Company has received notice of Mr Blower's resignation as a director with effect from 31 January 2010.

 

John Russell, Minster's Chairman, said: "We are grateful to Peter for his very significant contribution to Minster as an executive director over the last five years."

 

 

 

Enquiries

Minster Pharmaceuticals plc

Phone: +44 (0)20 7936 9921

John Russell, Chairman and Interim CEO

Karl Keegan, Chief Financial Officer

Buchanan Communications

Phone: +44 (0)20 7466 5000

Mark Court

Nomura Code Securities Limited

(Rule 3 Advisers & NOMAD)

Phone: +44 (0)20 7776 1200

Richard Potts, Giles Balleny

 

 

 

Dealing Disclosure Requirements

 

Under the provisions of the Rule 8.3 of the City Code, if any person is, or becomes, "interested" (directly or indirectly) in one per cent. or more of any class of "relevant securities" of Minster, all "dealings" in any "relevant securities" of that company (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3:30 p.m. (London Time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of Minster, they will be deemed to be a single person for the purpose of Rule 8.3.

 

Under the provisions of Rule 8.1 of the City Code, all "dealings" in "relevant securities" of Minster by Proximagen or Minster, or by any of their respective "associates", must be disclosed by no later than 12:00 noon (London Time) on the London business day following the date of the relevant transaction.

 

A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed, and the number of such securities in issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk.

 

"Interest in securities" arises, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having as "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

 

Terms in quotation marks are defined in the City Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, you should consult the Panel.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADMGGZZMRGGZM
Date   Source Headline
11th Dec 20181:21 pmRNSHolding(s) in Company
5th Dec 201811:24 amRNSHoldings in Company - Replacement
5th Dec 20189:05 amRNSHolding(s) in Company
4th Dec 20183:58 pmRNSHolding(s) in Company
4th Dec 20183:57 pmRNSHolding(s) in Company
30th Nov 20187:00 amRNSNew Business Division Within Mporium
14th Nov 20187:00 amRNSFundraising
2nd Nov 20187:00 amRNSNew strategic partnership with BPC
29th Oct 201811:24 amRNSHolding(s) in Company
3rd Oct 20187:00 amRNSUpdate on IMPACT's Sports Syncing technology
12th Sep 20187:00 amRNSBlock Admission Six Monthly Return
30th Aug 201810:04 amRNSDirector dealing
30th Aug 20187:00 amRNSHalf-year Report
18th Jul 20187:00 amRNSNew agency agreement for IMPACT
3rd Jul 20187:00 amRNSChange of Nominated Adviser and Broker
20th Jun 20187:00 amRNSIMPACT technology used by Performics for Samsung
30th May 20188:00 amRNSGrant of options
21st May 20189:59 amRNSResult of AGM
10th May 20189:17 amRNSHolding(s) in Company
9th May 20188:47 amRNSAnnual Report and Accounts and Notice of AGM
25th Apr 20187:00 amRNSFull Year Results
16th Mar 201812:01 pmRNSBLOCK ADMISSION SIX MONTHLY RETURN
13th Mar 20189:00 amRNSAppointment of Chief Operating Officer
26th Feb 20187:00 amRNSDirector dealing
23rd Feb 20188:31 amRNSGrant of options
23rd Feb 20187:00 amRNSBoard Changes
15th Feb 201811:39 amRNSDirector dealing
5th Jan 20187:00 amRNSNew agency agreement for IMPACT
22nd Dec 20177:00 amRNSResult of Fundraising
20th Dec 201711:15 amRNSProposed Subscription
15th Dec 20177:00 amRNSNew agency agreement for IMPACT
5th Dec 20177:00 amRNSContract for Fast Web Media
28th Nov 20177:00 amRNSNew agency agreement for IMPACT
21st Nov 20177:00 amRNSNew Commercial Agreement for IMPACT
6th Nov 20178:40 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
2nd Nov 20177:00 amRNSAppointment of Chief Technology Officer
1st Nov 20174:20 pmRNSHolding(s) in Company
1st Nov 20173:41 pmRNSRelease from Lock-in Agreement
29th Sep 201710:20 amRNSTotal Voting Rights
15th Sep 201710:39 amRNSBLOCK ADMISSION SIX MONTHLY RETURN
8th Aug 20177:01 amRNSBoard Changes
8th Aug 20177:00 amRNSHalf-year Report
25th Jul 20179:00 amRNSNotice of Results
21st Jun 20178:00 amRNSIndustry award and commercial agreement
18th May 20171:45 pmRNSResult of AGM
4th May 20175:04 pmRNSDirector/PDMR Shareholding
24th Apr 20177:00 amRNSFull Year Results
21st Mar 20177:00 amRNSResults of Placing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.